NCT04172753 Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac
| NCT ID | NCT04172753 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Rectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 472 participants |
| Start Date | 2018-05-09 |
| Primary Completion | 2022-05-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 472 participants in total. It began in 2018-05-09 with a primary completion date of 2022-05-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac radiotherapy hybrid device.
Eligibility Criteria
Inclusion Criteria: * existing indication for radiation therapy * minimum age 18 years, no upper age limit * capacity for consent * Informed consent Exclusion Criteria: * contraindication for MRI (claustrophobia, metallic implants not applicable for MRI * pregnancy
Frequently Asked Questions
Who can join the NCT04172753 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04172753 currently recruiting?
Yes, NCT04172753 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital Tuebingen to inquire about joining.
Where is the NCT04172753 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT04172753 clinical trial?
NCT04172753 is sponsored by University Hospital Tuebingen. The trial plans to enroll 472 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.